Redwood City biopharma startup hopes to raise up to $98M in what could be Bay Area's first IPO of 2018

The company is developing treatments for itchy skin disorders that it hopes will be approved by regulators in 2020.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.